Covered recipient · General Payments record
DOMINIC JOHN TITONE
Allopathic & Osteopathic Physicians Internal Medicine Critical Care Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$317.03
11 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $317.03 | 11 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $125.07 | 5 |
| Inspire Medical Systems, Inc. | $80.73 | 1 |
| Actelion Pharmaceuticals US, Inc. | $67.44 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.27 | 1 |
| GENZYME CORPORATION | $18.52 | 1 |
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DOMINIC JOHN TITONE
NPI 1184816159 · CMS profile ID 1109025
Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine
LAKEWOOD, CO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1184816159?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184816159?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184816159?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1184816159?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
11 matching records · $317.03 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–11 of 11.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | $80.73 | 11/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148118800 | CMS |
| Actelion Pharmaceuticals US, Inc. | $23.96 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078873840 | CMS |
| GlaxoSmithKline, LLC. | $26.50 | 07/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116716093 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.27 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117908362 | CMS |
| GlaxoSmithKline, LLC. | $25.34 | 06/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116602107 | CMS |
| Actelion Pharmaceuticals US, Inc. | $24.87 | 05/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078873846 | CMS |
| GlaxoSmithKline, LLC. | $23.30 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116395408 | CMS |
| GlaxoSmithKline, LLC. | $25.79 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115967119 | CMS |
| GlaxoSmithKline, LLC. | $24.14 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116663715 | CMS |
| GENZYME CORPORATION | $18.52 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139674260 | CMS |
| Actelion Pharmaceuticals US, Inc. | $18.61 | 01/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078873862 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $428,478.86 | 96 |
| PY2024 | Principal investigator | $715,381.10 | 49 |
| PY2023 | Principal investigator | $766,726.52 | 505 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
96 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $600.00 | 12/24/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211640212 |
| Principal investigator 1 | ModernaTX, Inc. | $6,848.55 | 12/17/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956587 |
| Principal investigator 1 | ModernaTX, Inc. | $103,970.25 | 12/05/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956601 |
| Principal investigator 1 | ModernaTX, Inc. | $4,116.82 | 12/01/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956593 |
| Principal investigator 1 | Genentech, Inc. | $3,800.00 | 11/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211640144 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 11/05/2025 | Non-covered Recipient Entity CRITICAL CARE PULMONARY AND SLEEP ASSOCIATES | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192185701 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $85.06 | 11/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817494 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.40 | 11/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817496 |
| Principal investigator 1 | ModernaTX, Inc. | $5,001.75 | 10/22/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 10/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783753 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 10/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817498 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 10/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817500 |
| Principal investigator 1 | ModernaTX, Inc. | $8,002.80 | 09/24/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956581 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $26,750.00 | 09/15/2025 | Non-covered Recipient Entity Qcare Site Services Inc | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226139772 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 09/03/2025 | Non-covered Recipient Entity CRITICAL CARE PULMONARY AND SLEEP ASSOCIATES | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192185692 |
| Principal investigator 1 | ModernaTX, Inc. | $6,002.10 | 09/02/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 09/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783751 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 09/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817534 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 09/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817536 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,800.00 | 08/15/2025 | Non-covered Recipient Entity Qcare Site Services, Inc Avacare | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220812908 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,135.00 | 08/06/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) | No dispute reported | 06/30/2026 | 1185549049 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 08/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783749 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 08/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817530 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 08/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817532 |
| Principal investigator 1 | ModernaTX, Inc. | $3,001.05 | 08/01/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956589 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 07/30/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211639917 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,800.00 | 07/26/2025 | Non-covered Recipient Entity Qcare Site Services, Inc Avacare | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220812995 |
| Principal investigator 1 | Genentech, Inc. | $729.00 | 07/25/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211639984 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,450.00 | 07/16/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185549055 |
| Principal investigator 1 | Genentech, Inc. | $900.00 | 07/16/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211639792 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $19,500.00 | 07/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244050622 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,000.00 | 07/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244050624 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,000.00 | 07/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244050626 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 07/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244050628 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 07/11/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244050630 |
| Principal investigator 1 | Genentech, Inc. | $372.00 | 07/04/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211640041 |
| Principal investigator 1 | ModernaTX, Inc. | $9,557.03 | 07/02/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 07/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783747 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 07/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817526 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 07/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817528 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,195.00 | 06/27/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA | No dispute reported | 06/30/2026 | 1185549045 |
| Principal investigator 1 | Genentech, Inc. | $9,268.00 | 06/18/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211639774 |
| Principal investigator 1 | Genentech, Inc. | $2,754.00 | 06/04/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 06/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783745 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 06/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817522 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 06/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817524 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 05/30/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589626 |
| Principal investigator 1 | ModernaTX, Inc. | $3,001.05 | 05/28/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956597 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $43,262.41 | 05/14/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185549053 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 05/14/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589889 |
| Principal investigator 1 | Genentech, Inc. | $1,438.00 | 05/07/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589575 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $179.90 | 05/06/2025 | Non-covered Recipient Entity QCARE SITE SERVICES | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244050714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 05/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783743 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 05/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817518 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 05/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817520 |
| Principal investigator 1 | ModernaTX, Inc. | $8,118.23 | 04/23/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956575 |
| Principal investigator 1 | ModernaTX, Inc. | $3,250.00 | 04/18/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 04/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783741 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 04/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817514 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 04/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817516 |
| Principal investigator 1 | ModernaTX, Inc. | $6,553.57 | 04/01/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956583 |
| Principal investigator 1 | Genentech, Inc. | $1,438.00 | 03/28/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589275 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 03/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 03/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $657.00 | 03/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $98.55 | 03/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783737 |
| Principal investigator 1 | Genentech, Inc. | $1,438.00 | 03/21/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589368 |
| Principal investigator 1 | Genentech, Inc. | $150.00 | 03/14/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589470 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,265.00 | 03/14/2025 | Non-covered Recipient Entity CRITICAL CARE PULMONARY AND SLEEP ASSOCIATES | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192185697 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,115.00 | 03/14/2025 | Non-covered Recipient Entity CRITICAL CARE PULMONARY AND SLEEP ASSOCIATES | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192185705 |
| Principal investigator 1 | ModernaTX, Inc. | $35,185.39 | 03/12/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956599 |
| Principal investigator 1 | Genentech, Inc. | $2,876.00 | 03/05/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589332 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 03/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783729 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 03/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817510 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 03/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817512 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $38,357.00 | 02/26/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 | No dispute reported | 06/30/2026 | 1185549051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 02/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | Ph2 PoC in IPF | No dispute reported | 06/30/2026 | 1220783755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 02/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | Ph2 PoC in IPF | No dispute reported | 06/30/2026 | 1220783757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $366.42 | 02/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | Ph2 PoC in IPF | No dispute reported | 06/30/2026 | 1220783759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $124.38 | 02/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | Ph2 PoC in IPF | No dispute reported | 06/30/2026 | 1220783761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.08 | 02/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | Ph2 PoC in IPF | No dispute reported | 06/30/2026 | 1220783763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 02/25/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | Ph2 PoC in IPF | No dispute reported | 06/30/2026 | 1220783765 |
| Principal investigator 1 | Genentech, Inc. | $1,438.00 | 02/05/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589024 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 02/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783727 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 02/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817506 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 02/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817508 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,798.71 | 01/29/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185549057 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,942.00 | 01/24/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA | No dispute reported | 06/30/2026 | 1185549047 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,500.00 | 01/17/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS LLC | A Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Investigate Efficacy, Safety, and Tolerability of LTP001 in Participants With Pulmonary Arterial Hypertension | No dispute reported | 06/30/2026 | 1190311191 |
| Principal investigator 1 | ModernaTX, Inc. | $1,250.00 | 01/15/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS LLC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956585 |
| Principal investigator 1 | Genentech, Inc. | $10,066.00 | 01/14/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589107 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 01/14/2025 | Non-covered Recipient Entity COGNITIVE CLINICAL TRIALS | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211589317 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 01/10/2025 | Non-covered Recipient Entity QCARE SITE SERVICES INC | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252956603 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 01/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220783739 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 01/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817502 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.00 | 01/01/2025 | Non-covered Recipient Entity Critical Care Pulmonary And Sleep Associates | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220817504 |